Cardiovascular

Merrill Stewart, MD, Ochsner Health, says insufficient funding from CMS for graduate medical education (GME) limits the ability to expand cardiology fellowships and contributes to the nationwide physician shortage.

Merrill H. Stewart, MD, Ochsner Health, explains how his practice takes advantage of downtime during cardiologist appointments to educate patients.

Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.

Merrill H. Stewart, MD, Ochsner Health, outlines the financial, logistical, and reimbursement barriers slowing the adoption of cardiac stress testing, but growing recognition of its long-term value could drive wider use.

Merrill H. Stewart, MD, Ochsner Health, explains misconceptions about stents and bypass surgery and highlights when cardiac positron emission tomography (PET) stress testing is most appropriate.

According to Merrill H. Stewart, MD, Ochsner Health, the test can more accurately identify high-risk patients while helping others avoid unnecessary invasive procedures.

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.

This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.

Offspring born to mothers with prepregnancy obesity, gestational diabetes, or hypertensive disorders of pregnancy had higher systolic and diastolic blood pressure levels than those born to mothers without these risk factors.

Experts share their final thoughts on the discussion, offering key takeaways and reflections on the importance of lipoprotein(a) (Lp[a]) testing and its role in improving cardiovascular risk management

A study comparing biological aging indicators found that Rockwood Frailty Index was a stronger predictor of cardiovascular disease (CVD) than leukocyte telomere length in adults without prior CVD.

Antoine Keller, MD, argued the value of grounding health care policy in equity as clinicians prepare for a changing health care landscape in the coming years.

A community-based remote patient monitoring (RPM) program was associated with significant reduction in blood pressure in Medicare patients with stage 2 hypertension, highlighting the potential benefits of RPM with care coaching.

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.

Experts discuss how guideline recommendations influence formulary decisions regarding preventive measures like lipoprotein(a) (Lp[a]) testing, exploring the varying recommendations from organizations such as the American Association of Clinical Endocrinologists, the American Heart Association, and the National Lipid Association (NLA), and how these align with recent guidance from Europe and Canada.

Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the best patient care and spread awareness to those who might be affected.

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.

Experts discuss an example illustrating the association between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk and explore how this example can inform our understanding of Lp(a) and ASCVD risk on a population level.

Experts discuss the genetic determinants of lipoprotein(a) (Lp[a]) levels, providing evidence supporting this conclusion. They also explore how the hereditary nature of Lp(a) can drive awareness of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis risk, potentially influencing screening protocols.

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.

Mobile self-management programs like that offered by Hello Heart can benefit employers and patients alike as they seek to manage and prevent heart disease.

Experts discuss the evidence supporting the continuous relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD), as recognized by the National Lipid Association, and explore how Lp(a) levels may change throughout a person’s lifetime or in response to lifestyle factors.

Experts discuss the relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk, with findings from a large US population study, and explore how these findings could impact clinical practice and the management of patients at risk for ASCVD.